Gossamer Bio, Inc. (GOSS) NASDAQ
0.20
+0.0008(+0.40%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Gossamer Bio, Inc.
Address
3013 Science Park Road
San Diego, CA 92121
United States of America (the)
Phone
858 684 1300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
144
First IPO Date
February 08, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Faheem Hasnain | Co-Founder, Chief Executive Officer, President & Chairman | 908,449 | 1958 |
| Christian Waage | EVP & General Counsel | 583,156 | 1967 |
| Robert Smith | Chief Commercial Officer | 663,713 | 1969 |
| Bryan Giraudo | Chief Operating Officer & Chief Financial Officer | 676,743 | 1975 |
| Richard Aranda | Chief Medical Officer | 677,492 | 1960 |
| Robert F. Roscigno | Senior Vice President of Clinical Development of Pulmonary Vascular Disease | 0 | 1966 |
| Conor O'Donovan | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Jeff Boerneke | General Counsel & Secretary | 0 | N/A |
| Louis K. Cherico | Senior Vice President of Finance & Treasury | 0 | N/A |
| Matt Cravets | Senior Vice President of Biometrics | 0 | N/A |
| Caryn L. Peterson | Executive Vice President of Regulatory Affairs | 0 | 1959 |
| Jeanine Anthony | Senior Vice President of Marketing | 0 | N/A |
| Kelly Dawson | Senior Vice President of Program Team Lead | 0 | N/A |
| Deanna Weber | Executive Vice President of Human Resources | 0 | N/A |
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
